SITE-SPECIFIC ENZYMATIC MODIFICATION OF EXENDINS AND ANALOGS THEREOF
There is provided inter alia a method of covalently attaching an amine derivatizing agent to a glutamine of a first polypeptide. The method includes adding an amine derivatizing agent, a transglutaminase a first polypeptide which includes a glutamine, and a co-solvent to a reaction mixture. The method further includes allowing the amine derivatizing agent to react with the glutamine of the first polypeptide in the reaction mixture to form an amide bond, thereby covalently attaching the amine derivatizing agent to the glutamine of the first polypeptide.
1 . A method of covalently attaching an amine derivatizing agent to a glutamine of a first polypeptide, said method comprising:
a) adding an amine derivatizing agent, a transglutaminase, a first polypeptide comprising a glutamine, and a co-solvent to a reaction mixture; and
b) allowing said amine derivatizing agent to react with said glutamine in said reaction mixture to form an amide bond;
thereby covalently attaching said amine derivatizing agent to said glutamine of said first polypeptide.
2 . The method according to claim 1 , wherein the extent of covalently attaching said amine derivatizing agent to said glutamine of said first polypeptide is at least 50%.
3 . (canceled)
4 . The method according to claim 1 , wherein said co-solvent is a first water-soluble polymer.
5 . The method according to claim 1 , wherein said reaction mixture comprises at least 5% (w/w) of said co-solvent.
6 . The method according to claim 5 , wherein said co-solvent is a glycol.
7 . The method according to claim 6 , wherein said glycol is propylene glycol or polyethylene glycol.
8 . The method according to claim 1 , wherein a lower concentration of side reaction products obtains relative to the corresponding method wherein said co solvent is absent from said reaction mixture.
9 . The method according to claim 8 , wherein said lower concentration of side reaction products is 25% or less relative to the corresponding method wherein said co solvent is absent from said reaction mixture.
10 . The method according to claim 1 , wherein said first polypeptide comprises a peptide hormone, or analog or fragment thereof.
11 . (canceled)
12 . The method according to claim 10 , wherein said first polypeptide comprises an amylin, pramlintide, adrenomedullin (ADM), calcitonin (CT), calcitonin gene related peptide (CGRP), intermedin, a cholecystokinin (CCK), a leptin, peptide YY (PYY), glucagon-like peptide-1 (GLP-1), glucagon-like peptide 2 (GLP-2), oxyntomodulin (OXM), a natriuretic peptide, a urocortin, a neuromedin family peptide, an exendin, or analog or fragment thereof.
13 . The method according to claim 12 , wherein said first polypeptide further comprises a linker.
14 - 15 . (canceled)
16 . The method according to claim 12 , wherein said first polypeptide comprises an exendin, or analog or fragment thereof.
17 . The method according to claim 16 , wherein said exendin analog has at least 80% sequence identity to exendin-4.
18 . (canceled)
19 . The method according to claim 16 , wherein said exendin is exendin-3 or exendin-4.
20 . The method according to claim 19 , wherein said exendin is exendin-4.
21 . The method according to claim 12 , wherein said amine derivatizing agent comprises an imaging label, a fluorescent label, a fatty acid, a bile acid, a glycan, a nasal delivery enhancing compound, biotin, cobalamine or derivative thereof, an amphiphilic oligomer, a second water soluble polymer, or a second polypeptide.
22 - 25 . (canceled)
26 . The method according to claim 21 , wherein said bile acid is cholic acid.
27 - 28 . (canceled)
29 . The method according to claim 21 , wherein said second water soluble polymer is polyethylene glycol.
30 . The method according to claim 21 , wherein said second polypeptide is an amylin, pramlintide, adrenomedullin (ADM), calcitonin (CT), calcitonin gene related peptide (CGRP), intermedin, a cholecystokinin (CCK), a leptin, peptide YY (PYY), glucagon-like peptide-1 (GLP-1), glucagon-like peptide 2 (GLP-2), oxyntomodulin (OXM), a natriuretic peptide, a urocortin, a neuromedin family peptide, an exendin, or analog or fragment thereof.
31 . The method according to claim 21 , wherein said second polypeptide comprises a linker.
32 . (canceled)